Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Pulmonary Cell News
Pulmonary Cell News is an online resource dedicated to the topics of respiratory disease, lung cancer, and pulmonary cells.
Downregulation of Mirlet7 miRNA Family Promotes Tc17 Differentiation and Emphysema via De-repression of RORγt
[eLife] The authors demonstrated that loss of the Mirlet7b/Mirlet7c2 cluster in T cells predisposed mice to exaggerated cigarette smoke- or nanosized carbon black-elicited emphysema.
Iron Overload–Dependent Ferroptosis Aggravates LPS-Induced Acute Lung Injury by Impairing Mitochondrial Function
[Inflammation] Investigators observed a significant increase in iron concentration during acute lung injury, accompanied by elevated levels of lipid peroxidation markers such as malonaldehyde and 4-hydroxynonenal.
β-Catenin Turnover Is Regulated by Nek10-Mediated Tyrosine Phosphorylation in A549 Lung Adenocarcinoma Cells
[Proceedings Of The National Academy Of Sciences Of The United States Of America] Investigators observed that deletion of Nek10 in lung adenocarcinoma cells resulted in dramatic stabilization of β-catenin, suggestive of a Nek10 role in the control of β-catenin turnover.
The Role of Gut-Lung Axis in COPD: Pathogenesis, Immune Response, and Prospective Treatment
[Heliyon] The authors summarize how the gut-lung axis influences COPD, including the alterations of intestinal microecology, the pathological mechanisms, and the involved immune responses.
Alectinib Approved as an Adjuvant Treatment for Lung Cancer
[National Cancer Institute] Based on the ALINA trial results, the FDA approved alectinib as adjuvant therapy for people with ALK-positive NSCLC.
Prime Editing Functionally Corrects Cystic Fibrosis-Causing CFTR Mutations in Human Organoids and Airway Epithelial Cells
[Cell Reports Medicine] Scientists presented prime editing approaches to correct L227R- and N1303K-CFTR, two mutations that caused cystic fibrosis and were not eligible for current market-approved modulator therapies.
Assessing Personalized Responses to Anti-PD-1 Treatment Using Patient-Derived Lung Tumor-on-Chip
[Cell Reports Medicine] The authors presented the development and validation of lung tumor-on-chip platforms to quickly and precisely measure ex vivo the effects of immune checkpoint inhibitors on T cell-mediated cancer cell death by exploiting the power of live imaging and advanced image analysis algorithms.
HMGN1 Loss Sensitizes Lung Cancer Cells to Chemotherapy
[Scientific Reports] Integrative analyses of multiple-omics data revealed that high mobility group nucleosome binding (HMGN) frequently exhibit dysregulation in lung adenocarcinoma (LUAD). Subsequent analysis of the clinical relevance of HMGN1 demonstrated its association with poor prognosis in LUAD and its potential as a diagnostic marker to differentiate LUAD from healthy controls.
Focal Adhesion Kinase-YAP Signaling Axis Drives Drug-Tolerant Persister Cells and Residual Disease in Lung Cancer
[Nature Communications] The authors integrated studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies.
METTL3-Mediated Deficiency of lncRNA HAR1A Drives Non-Small Cell Lung Cancer Growth and Metastasis by Promoting ANXA2 Stabilization
[Cell Death Discovery] Researchers identified the oncogenic protein annexin 2 (ANXA2) as a potential interacting patterner of highly accelerated region 1A (HAR1A). HAR1A overexpression enhanced ANXA2 ubiquitination and accelerated its degradation via the ubiquitin–proteasome pathway.
Neoadjuvant Nivolumab with or without Relatlimab in Resectable Non-Small-Cell Lung Cancer: A Randomized Phase II Trial
[Nature Medicine] In this ongoing, open-label Phase II study, 60 biomarker-unselected, treatment-naive patients with resectable NSCLC were randomized to receive two preoperative doses of nivolumab with or without relatlimab antibody therapy.
Targeting IL-11 to Reduce Fibrocyte Circulation and Lung Accumulation in Animal Models of Pulmonary Hypertension-Associated Lung Fibrosis
[British Journal of Pharmacology] Human fibrocytes were isolated from peripheral blood of six healthy donors. Recombinant human (rh)-IL-11 and soluble rh-IL-11 receptor, α subunit were used to stimulated fibrocytes in vitro to measure cell migration in a chemotactic migration chamber among other variables.
Spurred by advances in the modeling of the airway epithelium, Pulmonary Cell News was launched in 2012 to help scientists stay at the forefront of cutting edge research. Every week, our editors hand-select the most recent, top scientific journal articles on the topics of pulmonary cells, lung cancers, and respiratory diseases such as COPD and asthma. We also highlight current job postings and upcoming events to keep the global research community connected!
